CNX Therapeutics Acquires Sativex From Jazz Pharmaceuticals – RamaOnHealthcare

CNX Therapeutics expands CNS portfolio with Sativex acquisition

Sativex is indicated for the enhancement of symptoms in adult patients experiencing moderate to severe spasticity due to multiple sclerosis (MS) who have not responded sufficiently to other The post CNX Therapeutics expands CNS portfolio with Sativex acquisition appeared first on Pharmaceutical Business review.

CNX Therapeutics acquires Sativex from Jazz Pharmaceuticals – RamaOnHealthcare

Deal strengthens CNS portfolio and ensures continuity of access for MS patientsCNX Therapeutics has acquired the global Sativex (nabiximols) business from Jazz Pharmaceuticals, reinforcing its position in the central nervous system (CNS) therapeutic space. The transaction was completed on 31 October 2025 and includes marketing authorisations, commercial partnerships and manufacturing arrangements.Sativex is approved in the [...]

CNX Therapeutics acquires Sativex from Jazz Pharmaceuticals

Deal strengthens CNS portfolio and ensures continuity of access for MS patients